Clinical Trial Update: Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating rintatolimod in combination with celecoxib, interferon alfa-2b, and pembrolizumab for metastatic or unresectable triple-negative br…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Celecoxib (Celecoxib)
• Intron A (interferon alfa-2b)
• KEYTRUDA (PEMBROLIZUMAB)
• Rintatolimod (Ampligen) (polyinosinic:polycytidylic acid-poly-L-lysine-carboxymethylcellulose complex (poly-ICLC))

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma | Phase 1, Phase 2 | Status: TERMINATED